GO
Loading...

Analyst Interviews

Facebook: 3 investor concerns     Thu, 24 Apr '14 | 10:35 AM ET

Arvind Bhatia, Sterne Agee managing director & senior research analyst, and Scott Kessler, S&P Capital IQ senior equity analyst, discuss Facebook's mobile ad revenue and address investor concerns.

The case for CAT     Thu, 24 Apr '14 | 10:06 AM ET

Breaking down Caterpillar's Q1 earnings beat aided by cost cuts in is mining equipment business, with Ann Duignan, JPMorgan machinery & multi-industry analyst.

Apple is reporting Q2 EPS of $11.62 on revenue of $45.6 billion. Gene Munster, Piper Jaffray senior research analyst, says investors should feel a sense of relief on these numbers.

Ben Reitzes, Barclays technology hardware analyst, discusses earnings expectations and new innovation at Apple. Reitzes also weighs in on the tech giant's potential acquisition of Square.

YUM will grind higher: Analyst     Wed, 23 Apr '14 | 10:09 AM ET

David Palmer, RBC Capital Markets managing director, breaks down Yum! Brands' Q1 earnings that missed on their top line and discusses the company's China business.

Discussing McDonald's positive European profits and need for margin improvement in the U.S., with Jeffrey Bernstein, Barclays senior restaurant analyst.

McDonald's 'not broken story': Analyst     Tue, 22 Apr '14 | 8:33 AM ET

McDonald's reported Q1 EPS of $1.21 on revenue of $6.7 billion. RJ Hottovy of Morningstar, still sees value in the stock.

Reality for Netflix     Tue, 22 Apr '14 | 7:41 AM ET

BTIG media and tech analyst Rich Greenfield, questions why some of the bandwidth burden should or shouldn't fall on Netflix.

Keep buying Time Warner Cable: Analyst     Tue, 22 Apr '14 | 7:38 AM ET

Comcast reported $0.68 ex-items on revenue of $17.408 billion in Q1. BTIG media and tech analyst Rich Greenfield, discusses cable network advertising, and explains the opportunities that could arise from the Time Warner Cable and Comcast deal.

Ackman & Valeant's bid for Allergan     Tue, 22 Apr '14 | 7:04 AM ET

In an SEC Filing, Valeant Pharmaceuticals said it expected to offer a mix of stock and about $15 billion in cash for botox maker Allergan. David Krempa, Morningstar equity analyst, and CNBC's Meg Tirrell, provide perspective.

Netflix's Q1 earnings beat the Street's expectations. Will Power, Robert Baird senior research analyst, anticipates growth in the company for years. "The real story is international for Netflix," he says.

Michael Farr, Farr, Miller & Washington president; Greg McBride, Bankrate.com senior financial analyst; and CNBC's Jeff Cox, discuss a survey that indicates fewer Americans are inclined to invest in the stock market even with low interest rates.

Reasons to buy Yum! Brands     Mon, 21 Apr '14 | 3:28 PM ET

Debating if investors should be betting on Yum! Brands ahead of tomorrow's earnings report, with Peter Saleh, Telsey Advisory Group senior research analyst, and Andrew Keene, Keene on the Markets founder.

Netflix's international opportunity     Mon, 21 Apr '14 | 11:34 AM ET

Will Power, Robert W. Baird & Co. senior research analyst, discusses expectations the Q1 quarterly earnings of Netflix and their market opportunity in the U.S. and abroad. Henry Blodget, Business Insider, provides insight.

Analyst upgrades Netflix     Thu, 17 Apr '14 | 12:15 PM ET

Netflix was upgraded to "buy" at Pacific Crest. Analyst Andy Hargreaves, says the stock pulled back and the company's earnings potential has gone up.

MS story stronger, longer-term: Pro     Thu, 17 Apr '14 | 11:30 AM ET

Brennan Hawken, UBS director of equity research, breaks down the quarterly earnings of Morgan Stanley and Goldman Sachs.

Yahoo improves display business     Wed, 16 Apr '14 | 2:16 PM ET

Neil Doshi, CRT Capital internet analyst, makes the bull case for Yahoo sans Alibaba.

Commercial loans key XLF growth: Analyst     Wed, 16 Apr '14 | 11:36 AM ET

Discussing loan growth in financials and the drag of litigation on Bank of America's earnings, with Gerard Cassidy, RBC Capital Markets lead banking analyst.

CNBC's Rick Santelli and Gabe Petek, S&P Ratings analyst, discuss the credit outlook for state and local governments.

Mike Mayo: 'Definite buyer of Citi here'     Tue, 15 Apr '14 | 12:51 PM ET

CLSA analyst Mike Mayo discusses his remaining restructuring and regulator questions about Citigroup after the company's earnings beat, and why he is still a buyer.

Love biotech on correction: Trader     Tue, 15 Apr '14 | 12:40 PM ET

The FMHR traders debate the play on large cap versus small cap biotech stocks.

Top biotech analyst forecasts bottom     Tue, 15 Apr '14 | 12:37 PM ET

Discussing large cap versus small cap biotech stocks, and the hottest picks in the space, with Yaron Werber of Citi.

Global consumer banking weak: Pro     Mon, 14 Apr '14 | 10:38 AM ET

Erik Oja, S&P Capital IQ U.S. banks equity analyst, explains what contributed to Citi's better-than-expected earnings and why he lowered his price target on the bank.

Citigroup's 'clean beat'     Mon, 14 Apr '14 | 8:13 AM ET

Citigroup reported Q1 EPS of $1.30 ex-items on revenue of $20.12 billion. David Hilder, Drexel Hamilton, says the company is fully capitalized.

Alec Gutierrez, Kelley Blue Book senior market analyst, weighs in on the evidence that General Motors may have known of problems in models that were recalled in 2011.

Masters leader board     Fri, 11 Apr '14 | 12:57 PM ET

Mark Rofling, golf analyst at The Golf Channel, says Adam Scott is the best player in the world right now.

The "Fast Money Halftime Report" traders compete at Liberty National Golf Course.

Paul Miller, FBR Capital Markets managing director & head of financial institutions research, breaks down the mixed Q1 earnings results of JPMorgan and Wells Fargo.

Reasons to buy tech stocks     Fri, 11 Apr '14 | 9:45 AM ET

A quick look at the day's top stories on "Squawk Box," including a Wall Street analyst who breaks down some interesting buying opportunities in the Internet space

Intuitive Surgical dropped after the company's Q1 earnings showed a drop in revenue. Shagun Chadha, CRT Capital Group, thinks investors should sell the stock in April. CNBC's Herb Greenberg, weighs in.

Contact Analyst Interviews

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More

CEO Interviews